

*Company* , FRESENIUS MEDICAL CARE , *Issue* , 2009

*Content* , AT A GLANCE , *Language* , ENGLISH

AT A GLANCE 2009



Fresenius Medical Care

## FRESENIUS MEDICAL CARE

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.77 million individuals worldwide.

Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

MORE THAN 64,000

EMPLOYEES WORLDWIDE

MORE THAN 30

PRODUCTION SITES WORLDWIDE

MORE THAN 180,000

PATIENTS WORLDWIDE

MORE THAN 2,300

DIALYSIS CLINICS WORLDWIDE


## FACTS AND FIGURES

### OPERATING DATA

<i>\$ in millions</i>	2008	2007	Change in %
<b>Selected key figures</b>			
Net revenue	10,612	9,720	9 %
Earnings before interest and taxes (EBIT)	1,672	1,580	6 %
Net income	818	717	14 %
Earnings per ordinary share <i>in \$</i>	2.75	2.43	13 %
Dividend per ordinary share <i>in €</i>	0.58	0.54	7 %

### REVENUE BY REGION 2008

*\$ in millions*




### MARKET POSITION IN MAJOR PRODUCT GROUPS 2008

	Rank 1	Rank 2	Rank 3
Dialyzers	Fresenius Medical Care	Gambro	Asahi
Dialysis machines	Fresenius Medical Care	Gambro	Nikkiso
Hemodialysis concentrates	Fresenius Medical Care	Fuso	Gambro
Bloodlines	Fresenius Medical Care	Gambro	Kawasumi
Peritoneal dialysis products	Baxter	Fresenius Medical Care	Pisa

## DIALYSIS SERVICES WORLDWIDE 2008

Patients




— Frenesius Medical Care — competitors — continent

## BASIC SHARE DATA

	Ordinary share	Preference share
<b>Ticker Symbols</b>		
Frankfurt Stock Exchange	FME	FME3
New York Stock Exchange	FMS	FMS / P
<b>Security Identification numbers</b>		
WKN	578 580	578 583
ISIN	DE 0005785802	DE 0005785836
CUSIP	358029106	358029205
<b>Stock Markets</b>		
Germany	Frankfurt (Prime Standard)	
United States	New York Stock Exchange	

## MAJOR PRODUCTION SITES




01, US	WALNUT CREEK	04, MX	REYNOSA	07, FR	L'ARBRESLE	10, CN	JIANGSU
02, US	OGDEN	05, DE	ST. WENDEL	08, IT	CREMONA	11, JP	BUZEN
03, MX	GUADALAJARA	06, DE	SCHWEINFURT	09, JP	INUKAI		

## DIALYSIS PRODUCTS 2008

Market shares

32 % Fresenius Medical Care

22 % Baxter



15 % Gambro

31 % Others

## WORLDLEADER IN DIALYSIS

# CREATING A FUTURE WORTH LIVING. FOR PEOPLE. WORLDWIDE. EVERY DAY.

More than three decades of experience in dialysis, innovative research, the global leader in dialysis services and products – that is Fresenius Medical Care.

Patients with kidney disease can now look ahead with much more confidence thanks to our innovative technologies and treatment concepts.

We give them a future, one that offers them the best-possible quality of life.

We use the increasing demand for modern dialysis methods to our advantage and work consistently to enhance the Company's growth. Together with our employees, we focus on pursuing strategies that will enable us to uphold our technological leadership.

As a vertically integrated company, we offer products and services for the entire dialysis value chain.

The highest medical standards are our benchmark. This is our commitment to our patients, our partners in the healthcare system and our investors, who trust in the reliable performance and the future of Fresenius Medical Care.

## DIALYSIS MARKET

End-stage renal disease (ESRD) has a global dimension. By the end of 2008, approximately 2.30 million patients received treatment for ESRD. Around 1.77 million patients in more than 145 countries on all continents received renal replacement therapy in the form of dialysis. Approximately 530,000 kidney patients live with a transplanted kidney.

Of the 1.77 million patients that underwent dialysis treatment by the end of 2008, 1.58 million were treated with hemodialysis and about 190,000 received peritoneal dialysis. In a global comparison of treatment methods, hemodialysis therefore clearly dominates. More than 89% of all dialysis patients were treated with this method in 2008.

The global dialysis market for both the provider and product business grew by approximately 5% to about \$65 billion in 2008. The market can be segmented into dialysis products accounting for around \$10.5 billion and dialysis services (including renal pharmaceuticals) valued at around \$55 billion.

### PATIENTS – REGIONAL DEVELOPMENT

	2008	Change
North America	445,000	4–5%
U.S.	370,000	3–4%
Europe/Middle East/Africa	520,000	5–6%
EU	300,000	3–4%
Asia-Pacific	620,000	10–11%
Japan	290,000	3–4%
Latin America	185,000	7–8%
<b>WORLDWIDE</b>	<b>1,770,000</b>	<b>7%</b>

## FURTHER INFORMATION



Dialysis Compact –  
The function, diseases  
and treatments for  
the human kidney



Dialysis Compact –  
The invention, develop-  
ment and success  
of the artificial kidney



Dialysis Compact –  
The history and  
development of  
peritoneal dialysis

These brochures are available on the internet at [www.fmc-ag.com](http://www.fmc-ag.com)  
( Patient Care > Dialysis Information) or at:

### CONTACT

**Fresenius Medical Care**  
61346 Bad Homburg  
Germany  
Phone: + 49 6172 609 0  
<http://www.fmc-ag.com>

**Investor Relations**  
Phone: + 49 6172 609 2525  
Fax + 49 6172 609 2301  
E-mail: [ir@fmc-ag.com](mailto:ir@fmc-ag.com)

**Public Relations**  
Phone: + 49 6172 609 2302  
Fax + 49 6172 609 2294  
E-mail: [pr@fmc-ag.com](mailto:pr@fmc-ag.com)

**Fresenius Medical Care  
North America**  
Phone: +1 800 948 2538  
Fax : +1 615 345 5605  
E-mail: [ir@fmc-ag.com](mailto:ir@fmc-ag.com)

### IMPRINT

Subject to change.

Fresenius Medical Care AG & Co. KGaA  
Registered seat and commercial register:  
Hof an der Saale (Germany), HRB 4019  
Chairman of the Supervisory Board: Dr. Gerd Krick  
General partner: Fresenius Medical Care Management AG  
Registered seat and commercial register:  
Hof an der Saale (Germany), HRB 3894  
Management Board: Dr. Ben Lipps (Chairman),  
Roberto Fusté, Dr. Emanuele Gatti, Rice Powell, Lawrence  
A. Rosen, Dr. Rainer Runte, Mats Wahlstrom  
Chairman of the Supervisory Board: Dr. Ulf M. Schneider